Similarly, a preclinical study in AML-bearing mice observed that the peptidic CXCR4 antagonist LY2510924 was capable of mobilising AML cells, had potent antileukemia activity and strongly synergised with cytotoxic chemotherapy [132]. Here, CXCR4 is linked to acute myeloid leukemia.